| Recruiting | MenB-FHbp or MenACWY-TT/MenB-FHbp Vaccine in MenB-4C Primed Young Adults NCT07197762 | Emory University | Phase 4 |
| Completed | Study to Assess Oropharyngeal Carriage of N. Meningitidis in South Australian School Leavers NCT03419533 | University of Adelaide | — |
| Completed | Investigating Meningococcal Vaccines in Adults NCT02398396 | University of Oxford | N/A |
| Completed | Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix® NCT01978093 | GlaxoSmithKline | Phase 3 |
| Completed | Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010) NCT01839188 | MCM Vaccines B.V. | Phase 3 |
| Completed | Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in H NCT01839175 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Neisseria Meningitidis Burden of Disease Study NCT01730391 | GlaxoSmithKline | — |
| Completed | Evaluation of Immune Response Against the Strain of Neisseria Meningitidis B: 14, P1-7, 16 in Patients Having NCT01621945 | University Hospital, Rouen | — |
| Completed | Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011) NCT01553279 | MCM Vaccines B.V. | Phase 3 |
| Completed | NeisVac-C Single Prime Study in Infants NCT01218451 | Pfizer | Phase 3 |
| Completed | Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants NCT01090453 | GlaxoSmithKline | Phase 2 |
| Completed | Study to Evaluate GSK Biologicals' GSK2197870A Vaccine Given as Primary Course in Infants NCT00871338 | GlaxoSmithKline | Phase 2 |
| Completed | Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hi NCT00891176 | GlaxoSmithKline | Phase 3 |
| Terminated | Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months NCT00871741 | GlaxoSmithKline | Phase 2 |
| Completed | Dose Comparison Study of Menactra® in US Children NCT00700635 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Primary & Booster Study to Evaluate the Immunogenicity and Safety of Menitorix Vaccine in Preterm Infants NCT00586612 | GlaxoSmithKline | Phase 3 |
| Completed | Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age. NCT00345683 | GlaxoSmithKline | Phase 3 |
| Completed | Study of Long-term Antibody Persistence After a Booster Dose of Menitorix Vaccine NCT00454987 | GlaxoSmithKline | Phase 4 |
| Completed | Immunogenicity and Safety of Menactra® Vaccine in Adolescents in Saudi Arabia NCT00444951 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 2, 4, 6 and 12 to 15 Months of NCT00345579 | GlaxoSmithKline | Phase 3 |
| Completed | Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccin NCT00359983 | GlaxoSmithKline | Phase 3 |
| Completed | Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to NCT00326118 | GlaxoSmithKline | Phase 3 |
| Completed | Long-term Persistence Study to Assess a Booster Dose of GSK Biologicals' Hib-MenC NCT00322335 | GlaxoSmithKline | Phase 3 |
| Completed | Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Va NCT00327184 | GlaxoSmithKline | Phase 3 |
| Completed | Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine NCT00289783 | GlaxoSmithKline | Phase 3 |
| Completed | Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines NCT00134719 | GlaxoSmithKline | Phase 2 |
| Completed | Safety, Reactogenicity & Immunogenicity Study to Evaluate a Booster Dose of GSK Biologicals' Hib-MenC Given Wi NCT00263653 | GlaxoSmithKline | Phase 3 |
| Completed | Primary & Booster Immunogenicity Study of GSK Biologicals' Hib-MenC Versus a Licensed Men-C Vaccine NCT00258700 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Reactogenicity of a Meningococcal B Outer Membrane Vesicle Vaccine Given in a 0,6,12 Month NCT00197795 | Public Health England | Phase 2 |
| Completed | Study of a Booster Dose of Hib-MenC Conjugate Vaccine vs Infanrix Hexa When Given to 14 Month Old Subjects NCT00323050 | GlaxoSmithKline | Phase 3 |
| Completed | Comparison of GSKBiologicals' Hib-MenCY-TT Vaccine vs Licensed Hib Conjugate or Meningococcal Vaccine NCT00129129 | GlaxoSmithKline | Phase 2 |
| Completed | Study of Reduced Dose of Menomune® in Children Who Previously Received Meningococcal Diphtheria Toxoid Conjuga NCT00772070 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | 3 Formulations of Hib-MenCY-TT Vaccine & 1 Formulation of Hib-MenC-TT Vaccine Compared to Licensed Meningococc NCT00129116 | GlaxoSmithKline | Phase 2 |
| Completed | Dose Ranging Study of Combined Haemophilus Influenzae Type B-Meningococcal Serogroups CY (Hib-MenCY-TT) Vaccin NCT00127855 | GlaxoSmithKline | Phase 2 |